Cancer Family
Sarcoma
CI-CAN-00000344SARExplore in graph →
634 active trials17 approved drugs182 evidence items
- NCIt
- C9118
- OncoTree
- SARCNOS
- DOID
- 1115
- MeSH
- D012509
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000344SARExplore in graph →
Clinical trials
2,687 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 |
| clinicaltrials |
| NCT05106777 | Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma | active not recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02846987 | Study of Abemaciclib in Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 33 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT00077285 | Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma | active not recruiting | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03114527 | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | active not recruiting | Phase 2 | 48 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03643133 | Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients(SARCOME13) | active not recruiting | Phase 2 | 60 | UNICANCEROTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03598595 | Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma | active not recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03414229 | A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04278781 | AG-120 in People With IDH1 Mutant Chondrosarcoma | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04784247 | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04968106 | Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)(TORNADO) | active not recruiting | Phase 2 | 66 | Institut BergoniéOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04028063 | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | active not recruiting | Phase 2 | 65 | University of Colorado, DenverOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT01864109 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | active not recruiting | Phase 2 | 83 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04189783 | Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05440786 | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | active not recruiting | Phase 2 | 46 | Eli Lilly and CompanyINDUSTRY | 7 | Apr 13, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT00186992 | Radiation Therapy to Treat Musculoskeletal Tumors | active not recruiting | Phase 2 | 202 | St. Jude Children's Research HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04288375 | Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs | active not recruiting | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03474094 | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy(RT-Immune) | active not recruiting | Phase 2 | 62 | Centre Leon BerardOTHER | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04562480 | Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk | active not recruiting | Phase 2 | 120 | Mayo ClinicOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04599062 | TVEC and Preop Radiation for Sarcoma (8 ml Dose) | active not recruiting | Phase 1 / Phase 2 | 8 | John RiethOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT03899792 | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors(LIBRETTO-121) | active not recruiting | Phase 1 / Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 11 | Jan 6, 2026 | clinicaltrials |
| NCT06128863 | Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial(EFTISARC-NEO) | active not recruiting | Phase 2 | 40 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04551430 | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | active not recruiting | Phase 2 | 105 | Washington University School of MedicineOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04803877 | SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | active not recruiting | Phase 2 | 48 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05886634 | A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05809830 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas(Enhancer) | active not recruiting | Phase 1 / Phase 2 | 152 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT03778996 | SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma(HopES) | active not recruiting | Phase 2 | 31 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04733183 | Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma(FLASH) | active not recruiting | Phase 2 | 98 | Philogen S.p.A.INDUSTRY | 5 | Jan 27, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials